QR Code

Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells

Summary: Renal cell carcinoma (RCC) represents about 90% of kidney cancers, with 30%–40% of patients developing metastatic disease despite current treatments. Conventional chimeric antigen receptor (CAR)-T therapy targeting CD70 shows promise but faces challenges due to its autologous, personalized...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Yan-Ruide Li, Junhui Hu, Zhe Li, Enbo Zhu, Yuning Chen, Tyler Halladay, Xinyuan Shen, Ying Fang, Yichen Zhu, Zibai Lyu, Yanxin Tian, Jie Huang, Annabel S. Zhao, Nathan Y. Ma, Catherine Zhang, Yongpeng Xie, Hanwei Zhang, Tzung Hsiai, Arnold I. Chin, Lily Wu, Lili Yang
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Elsevier 2025-09-01
Rangatū:Cell Reports Medicine
Ngā marau:
Renal cell carcinoma
RCC
CD70
invariant natural killer T cell
NKT cell
CAR-NKT cell
Urunga tuihono:http://www.sciencedirect.com/science/article/pii/S2666379125003945
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite